High burden of adverse events is associated with reduced remission rates in early rheumatoid arthritis-Reference-Cited by-同舟云学术

High burden of adverse events is associated with reduced remission rates in early rheumatoid arthritis

Published:2017-12-26 Issue:6 Volume:37 Page:1689-1694
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Kuusalo Laura^ORCID, ,Puolakka Kari,Kautiainen Hannu,Karjalainen Anna,Malmi Timo,Paimela Leena,Leirisalo-Repo Marjatta,Rantalaiho Vappu

Funder

Finnish Rheumatology Research Foundation

Turun Yliopistosäätiö

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

http://link.springer.com/article/10.1007/s10067-017-3958-1/fulltext.html

Reference18 articles.

1. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Porter D, Kincaid W (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364(9430):263–269. https://doi.org/10.1016/S0140-6736(04)16676-2

2. Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M, Järvinen P, Ahonen J, Forsberg S, Leirisalo-Repo M, FIN-RACo Trial Group (2005) Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 52(1):36–41. https://doi.org/10.1002/art.20716

3. Aletaha D, Smolen JS (2002) The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology 41(12):1367–1374. https://doi.org/10.1093/rheumatology/41.12.1367

4. Agarwal S, Zaman T, Handa R (2009) Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Singap Med J 50:686–692

5. Cummins L, Katikireddi VS, Shankaranarayana S, KY S, Duggan E, Videm V et al (2015) Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis. Intern Med J 45(12):1266–1273. https://doi.org/10.1111/imj.12896

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept;Expert Opinion on Drug Safety;2023-01-27

2. Evaluation of a medication optimization intervention and predictors of medication adherence, patient satisfaction and medication adverse events in patients with rheumatoid arthritis;Musculoskeletal Care;2021-09-16

3. Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial;The Lancet Diabetes & Endocrinology;2020-04

4. Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis;Expert Review of Pharmacoeconomics & Outcomes Research;2019-08-01

5. Impact of Adverse Events Associated With Medications in the Treatment and Prevention of Rheumatoid Arthritis;Clinical Therapeutics;2019-07